Regeneron Pharmaceuticals Inc. and partner Sanofi SA will launch pivotal studies of the potential blockbuster allergy therapeutic dupilumab (REGN668/SAR231893) by the end of this year on the heels of encouraging phase IIb data showing it helped clear skin lesions in patients with a serious, chronic and hereditary form of eczema called atopic dermatitis (AD).